Drugs / Secnidazole
Secnidazole
also known as
SYM-1219 · Deprozol · Flagentyl · NSC-759812 · Ornidazole metabolite m4 · PM-185184 · RP 14539 · Sabima · +5 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | SOLOSEC | — | 2021-06-30 – 2022-01-26 | fda.gov ↗ |
| Approved | US (FDA) | SOLOSEC | — | 2017-09-15 | fda.gov ↗ |
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01019083 | Feb 2008 → Dec 2010 | cholera, typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02147899 | May → Oct 2014 | bacterial vaginosis | Symbiomix Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05033743 | Jul 2021 → Oct 2022 | bacterial vaginosis | Indiana University | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03935217 | Apr 2019 → Mar 2020 | trichomoniasis | Lupin Research Inc | Completed | No outcome recorded |
| Phase 3 | NCT02452866 | Jun → Oct 2015 | bacterial vaginosis | Symbiomix Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02418845 | May → Oct 2015 | bacterial vaginosis | Symbiomix Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02111629 | May 2012 → Feb 2013 | vaginal discharge | National University of Colombia | Completed | No outcome recorded |
| Phase 3 | NCT01733966 | May 2010 → Mar 2012 | diverticulitis of colon | Quanta Medical | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06261840 | May 2025 → May 2029 expected | Trichomonas vaginitis urogenital infection, bacterial vaginosis | Tulane University | Recruiting | No outcome recorded |
| Phase 4 | NCT03937869 | Nov 2018 → Nov 2020 | bacterial vaginosis | Lupin Research Inc | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00607074 | Jun 2003 → Apr 2004 | giardiasis | University of Cambridge | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secnidazole | “Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of...” NCT02452866 ↗ |
| Known as | Deprozol | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Flagentyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | NSC-759812 | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Ornidazole metabolite m4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | PM-185184 | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | RP 14539 | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Sabima | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Secnidal | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Secnidazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Secnidazole anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Secnol | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | Solosec | ChEMBL registry synonym — accepted as the source's own label CHEMBL498847 ↗ |
| Known as | SYM-1219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02147899 ↗ |
| Modality | Small molecule | “a next generation 5-nitroimidazole” PMID 42031495 ↗ Apr 2026 |
| Route | Oral | “a single oral dose of a combined treatment with secnidazole + fluconazole” NCT02111629 ↗ |